Maat Pharma SA
PAR:MAAT

Watchlist Manager

Maat Pharma SA

PAR:MAAT

Watchlist

Discount Rate

Price: 7.3 EUR 2.24% Market Closed

Market Cap: 101.4m EUR

Have any thoughts about
Maat Pharma SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	Abbvie Inc NYSE:ABBV	Biotechnology
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Realty Income Corp NYSE:O	Real Estate
US	Walt Disney Co NYSE:DIS	Media
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 7.3 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

MAAT Alert

Maat Pharma SA

7.3

+0.16 (+2.24%)

52 Week Range	4.92 9.6
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	Abbvie Inc NYSE:ABBV	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Realty Income Corp NYSE:O	US
	Walt Disney Co NYSE:DIS	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Maat Pharma SA

What unique competitive advantages
does Maat Pharma SA hold over its rivals?

What risks and challenges
does Maat Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Maat Pharma SA.

What unique competitive advantages
does Maat Pharma SA hold over its rivals?

What risks and challenges
does Maat Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Maat Pharma SA.

Provide P/S
for Maat Pharma SA.

Provide P/E
for Maat Pharma SA.

Provide P/OCF
for Maat Pharma SA.

Provide P/FCFE
for Maat Pharma SA.

Provide P/B
for Maat Pharma SA.

Provide EV/S
for Maat Pharma SA.

Provide EV/GP
for Maat Pharma SA.

Provide EV/EBITDA
for Maat Pharma SA.

Provide EV/EBIT
for Maat Pharma SA.

Provide EV/OCF
for Maat Pharma SA.

Provide EV/FCFF
for Maat Pharma SA.

Provide EV/IC
for Maat Pharma SA.

Show me price targets
for Maat Pharma SA made by professional analysts.

What are the Revenue projections
for Maat Pharma SA?

How accurate were the past Revenue estimates
for Maat Pharma SA?

What are the Net Income projections
for Maat Pharma SA?

How accurate were the past Net Income estimates
for Maat Pharma SA?

What are the EPS projections
for Maat Pharma SA?

How accurate were the past EPS estimates
for Maat Pharma SA?

What are the EBIT projections
for Maat Pharma SA?

How accurate were the past EBIT estimates
for Maat Pharma SA?

Compare the revenue forecasts
for Maat Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Maat Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Maat Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Maat Pharma SA compared to its peers.

Compare the P/E ratios
of Maat Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Maat Pharma SA with its peers.

Analyze the financial leverage
of Maat Pharma SA compared to its main competitors.

Show all profitability ratios
for Maat Pharma SA.

Provide ROE
for Maat Pharma SA.

Provide ROA
for Maat Pharma SA.

Provide ROIC
for Maat Pharma SA.

Provide ROCE
for Maat Pharma SA.

Provide Gross Margin
for Maat Pharma SA.

Provide Operating Margin
for Maat Pharma SA.

Provide Net Margin
for Maat Pharma SA.

Provide FCF Margin
for Maat Pharma SA.

Show all solvency ratios
for Maat Pharma SA.

Provide D/E Ratio
for Maat Pharma SA.

Provide D/A Ratio
for Maat Pharma SA.

Provide Interest Coverage Ratio
for Maat Pharma SA.

Provide Altman Z-Score Ratio
for Maat Pharma SA.

Provide Quick Ratio
for Maat Pharma SA.

Provide Current Ratio
for Maat Pharma SA.

Provide Cash Ratio
for Maat Pharma SA.

What is the historical Revenue growth
over the last 5 years for Maat Pharma SA?

What is the historical Net Income growth
over the last 5 years for Maat Pharma SA?

What is the current Free Cash Flow
of Maat Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Maat Pharma SA.

EV/EBITDA
Enterprise Value to EBITDA

-4.6

Current

-6.6

Median

5.1

Industry

Higher than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-4.6

Enterprise Value

87.7m EUR

EBITDA

-19.1m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
FR	M	Maat Pharma SA PAR:MAAT	101.4m EUR	-4.6
US		Abbvie Inc NYSE:ABBV	341.9B USD	15.8
US		Amgen Inc NASDAQ:AMGN	180.5B USD	20.2
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	127.8B USD	25.9
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	123.3B USD	26.8
US		Gilead Sciences Inc NASDAQ:GILD	104.5B USD	9.4
US	E	Epizyme Inc F:EPE	94.1B EUR	-550.7
AU		CSL Ltd ASX:CSL	142.3B AUD	22.4
US	S	Seagen Inc F:SGT	39.3B EUR	-63
US	P	Palatin Technologies Inc LSE:0KF3	38.5B USD	-1 185.3
US		Alnylam Pharmaceuticals Inc NASDAQ:ALNY	35.4B USD	213.7

				EBITDA Growth
FR	M	Maat Pharma SA PAR:MAAT	Average EV/EBITDA: 47.7 Negative Multiple: -4.6	N/A
US		Abbvie Inc NYSE:ABBV	15.8	28%
US		Amgen Inc NASDAQ:AMGN	20.2	57%
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	25.9	47%
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	26.8	39%
US		Gilead Sciences Inc NASDAQ:GILD	9.4	10%
US	E	Epizyme Inc F:EPE	Negative Multiple: -550.7	N/A
AU		CSL Ltd ASX:CSL	22.4	45%
US	S	Seagen Inc F:SGT	Negative Multiple: -63	N/A
US	P	Palatin Technologies Inc LSE:0KF3	Negative Multiple: -1 185.3	N/A
US		Alnylam Pharmaceuticals Inc NASDAQ:ALNY	213.7	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-2.9

2-Years Forward

EV/EBITDA

-3.1

3-Years Forward

EV/EBITDA

-5

Maat Pharma SA
PAR:MAAT

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Maat Pharma SA PAR:MAAT

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Maat Pharma SA
PAR:MAAT

EV/EBITDA
Enterprise Value to EBITDA